SCHEMBL5386587

SCHEMBL5386587

Cc1nc2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)nn2c(O)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 4/20 0.40
NPC1 O15118 3/20 0.39
RAB9A P51151 2/20 0.39
NPSR1 Q6W5P4 1/20 0.38
CNR1 P21554 5/20 0.38
CNR2 P34972 3/20 0.38
KDM4E B2RXH2 4/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
HTT P42858 1/20 0.37
PTGS2 P35354 2/20 0.37
PTGS1 P23219 1/20 0.37
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5375193 0.88 TP53 (0.43) TP53MAPTMEN1KMT2AALDH1A1
SCHEMBL5391337 0.84 MAPT (0.49) TP53MAPTMEN1KMT2AALDH1A1
SCHEMBL5386233 0.81 KMT2A (0.46) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL25362655 0.81 CNR1 (0.38) TP53MAPTMEN1KMT2AALDH1A1
SCHEMBL4832926 0.80 CNR1 (0.45) TP53MAPTMEN1KMT2AALDH1A1
SCHEMBL8261401 0.80 CNR1 (0.45) TP53MAPTMEN1KMT2AALDH1A1
SCHEMBL14577345 0.79 MEN1 (0.62) TP53MAPTMEN1KMT2AALDH1A1
SCHEMBL5375242 0.79 MAPT (0.64) TP53MAPTMEN1KMT2AALDH1A1
SCHEMBL5375812 0.77 NPC1 (0.45) TP53MAPTMEN1KMT2AALDH1A1
SCHEMBL25358857 0.77 MAPT (0.48) TP53MAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
EP-1594872-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2005-11-16 EP disclosed
WO-2004069838-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2004-08-19 WO disclosed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 TP53 4878/4885MAPT 2827/4885MEN1 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.